Relay Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Relay Therapeutics, Inc. (Nasdaq: RLAY) is a clinical-stage precision medicine company that transforms drug discovery by integrating computational and experimental technologies via its proprietary Dynamo platform to target previously intractable protein motion for small-molecule therapeutics in precision oncology and genetic diseases. Founded in 2015 and headquartered in Cambridge, Massachusetts, the company advances a pipeline including RLY-2608, a pan-mutant selective PI3Kα inhibitor in Phase 3 (ReDiscover-2) for PIK3CA-mutated, HR+/HER2- metastatic breast cancer and Phase 2 (ReInspire) for PIK3CA-related vascular malformations; RLY-8161, an NRAS-selective inhibitor for NRAS-driven solid tumors advancing toward clinical development in the second half of 2025; αGal, a program for Fabry disease with clinical start planned for the second half of 2025; and lirafugratinib (RLY-4008), an FGFR2 inhibitor globally outlicensed to Elevar Therapeutics. Relay Therapeutics operates primarily in the United States with international clinical trial reach and maintains ongoing collaborations with D.E. Shaw Research for computational modeling, Pfizer for RLY-2608 combination therapies in breast cancer, and Elevar Therapeutics, which includes a late 2024 licensing deal providing up to $500 million in milestones and low-teens royalties. Recent advancements encompass disclosure of three new preclinical programs in June 2024 targeting vascular malformations, Fabry disease, and NRAS; positive Phase 3 progression-free survival data for RLY-2608; and a cash position of $596.4 million as of September 30, 2025, supporting operations into late 2026 amid cost-saving measures.
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
Is Relay Therapeutics a Buy After Promising Trial Results?
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Why Relay Therapeutics Stock Popped on Wednesday
Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise
Relay Therapeutics, Inc. (RLAY) Discusses Initial Clinical Data for Zovegalisib in Vascular Anomalies Transcript
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Relay's treatment shown to shrink vascular malformations in mid-stage trial
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
JPMorgan Chase & Co. Reduces Position in Relay Therapeutics, Inc. $RLAY
Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?
SG Americas Securities LLC Acquires 189,004 Shares of Relay Therapeutics, Inc. $RLAY
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of “Moderate Buy” from Analysts